Opioid Advisory Task Force
President Eric Kaler has stated that the University of Minnesota must leverage its expertise—from basic neuroscience to psychology to law—for the benefit of Minnesotans and Minnesota communities affected by opioid addiction, and that the University must also be prepared for possible new research opportunities related to this current public health and societal emergency.
The University of Minnesota Opioid Advisory Task Force, organized by the Office of the Vice President for Research (OVPR), is composed of faculty who will review, discuss, and prioritize the activities at a systemwide level. Specifically, the task force will:
- Prepare our community of scholars to respond to research opportunities that can help advance our knowledge of addiction and pain management
- Assist leaders in the Academic Health Center to evaluate how and whether medical and health professional students are receiving training relevant to best practices in pain management, addiction prevention, and overdose prevention
- Evaluate and organize what the University can offer to Minnesota communities as they cope with direct and indirect effects of the opioid addiction epidemic
- Engage with public officials in relevant discussions of public policy, all in cooperation with Government Relations and other units across the University
The Office of the Vice President for Research (OVPR) is inventorying opioid-related work across the system, creating a list of more than 130 faculty and staff thus far.
Some prominent examples include:
- Medical Discovery Team on Addiction, funded by the State of Minnesota in 2014
- U of M Center for Addiction Neuroscience (UMnCAN), formed in 2016 to coordinate the efforts of dozens of clinical and basic research scientists
- Minnesota Center for Chemical and Mental Health (MNCAMH), helps Minnesota’s clinical workforce become better equipped to support individuals experiencing mental health, substance use and co-occurring disorders
- Master of Professional Studies in Addictions Counseling (ADDC), prepares counselors to treat clients with substance use disorders
There are many other efforts that we hope to capture and highlight in the coming months.
OVPR has identified several existing University of Minnesota grant programs applicable to opioid-related research. See this list of Possible Internal Funding Sources for Opioid-Related Research. Please note that the University's Fall 2018 Grant-in-Aid funding competition is now open with a special category added for Opioid-related research.
After consultation with U of M chancellors, deans, and the Academic Health Center, OVPR has asked a smaller group to serve on the Opioid Advisory Task Force Leadership Committee:
Tim Ebner, Medical School, Neuroscience
Tim Ebner is Head of the Department of Neuroscience at the UMN Medical School. His laboratory is trying to understand how single neurons and populations of neurons encode the information needed to plan and execute limb movements. The goal is to decipher how the brain represents different movement parameters and then uses this information to control movements.
Carolyn Fairbanks, College of Pharmacy, Pharmaceutics
Carolyn Fairbanks develops non-addictive analgesic medications to treat chronic pain and treatments for opioid addiction. She also uses pre-clinical models of opioid addiction and relapse in the context of chronic pain to understand how the reward centers may be altered under the condition of chronic pain.
Ralph Hall, Law School
Ralph Hall is a professor of practice at the UMN Law School. An expert on FDA and related regulatory issues, Ralph is actively engaged in policy matters with Congress and the FDA.
Pinar Karaca-Mandic, Carlson School of Management, Finance (MILI)
Pinar Karaca-Mandic teaches economics of healthcare marketplace, health finance and medical technology evaluation, including as related to pharmaceutical use. She has published on issues related to opioid prescribing by physicians and hospitals, and is also the PI on a new grant by American Cancer Society to study the entry and uptake of biosimilar drugs in the U.S. markets.
Kerry Michael, U of M-Morris, Psychology
Kerry Michael is a professor of psychology at UMN Morris. She is the co-PI on a grant to evaluate drug court program in MN Eighth Judicial District.
Thomas Molitor, College of Veterinary Medicine, Population Medicine
Thomas Molitor is Department Chair and Professor of the Department of Veterinary Population Medicine, as well as adjunct in the Medical School. He researches the interactions of drugs of abuse with the nervous and immune systems, and integrates our understanding of these physiological interactions with their behavioral counterparts.
Laura Palombi, College of Pharmacy, Duluth; Department of Pharmacy Practice and Pharmaceutical Sciences
Laura Palombi is an assistant professor and community-based participatory action researcher focused on preventing and addressing substance abuse. She has been involved in a variety of projects and collaborations in Northeastern Minnesota, including memberships on numerous rural coalitions and partnerships with public health departments. She has affiliate appointments in the School of Public Health and Center for Bioethics.
Marizen Ramirez, School of Public Health, Division of Environmental Health Sciences
Injuries and violence are topics of interest to Marizen Ramirez, an epidemiologist who studies effective and evidence-based solutions. She has a special focus on vulnerable populations such as children, persons with disabilities, agricultural workers, minorities, and people in rural areas. With opioid overdose now the number one cause of injury death in the United States, she is beginning to explore risk factors and measures to prevent and respond to the opioid epidemic.
Charles Reznikoff, Medical School, Medicine
Charles Reznikoff participates in the Minnesota Department of Human Service Opioid Provider Work Group. He collaborates with the Institute for Clinical Systems Improvement to improve consistency of opioid prescribing and addiction treatment statewide. He also works with the Minnesota Medical Association and the Steve Rummler Hope Network to develop curriculum for medical students and providers to better prescribe opioids and treat opioid addiction.
Mark Thomas, Medical School, Neuroscience
Mark Thomas studies brain pathways and stimulation to prevent drug addiction relapse. These studies will provide insight into the cellular and molecular mechanisms of an important form of experience-dependent plasticity that may hold some of the clues to drug addiction.
Harold Tu, School of Dentistry, Developmental and Surgical Sciences
Harold Tu is Director of the Division of Oral and Maxillofacial Surgery at the UMN School of Dentistry, as well as an associate professor. His research includes non-opioid protocol in managing acute postoperative pain. He also studies opioid knowledge and prescriber behavior of dental students, residents and faculty.
Deb Wamsley, College of Continuing and Professional Studies
Debra Wamsley has spent most of her career providing evidence-based care for co-occurring addictions and mental health concerns. In addition to primary care, her interests include advocacy and dispelling disparate access and resources for underserved communities.
George Wilcox, Medical School, Neuroscience
George Wilcox’s research is focused on neural mechanisms of opioid analgesia and analgesic synergy in spinal cord and peripheral tissues. He and his team have developed a non-addictive combination opioid treatment that lacks the CNS side effects like respiratory depression and addiction liability.
NIH releases two HEALing Communities Study opportunities, September 19, 2018
NIH and SAMSHA are partnering to launch the HEALing Communities Study, which is designed to determine if an integrated set of evidence-based interventions within healthcare, behavioral health, justice systems, and community organizations can work to decrease opioid overdoses and to prevent and treat opioid use disorders.
NIH Launches Acute to Chronic Pain Signatures Program, August 28, 2018
NIH launched its Acute to Chronic Pain Signatures (A2CPS) program to “investigate the biological characteristics underlying the transition from acute to chronic pain.” The program will expand research on what mechanisms make some people susceptible and other resilient to developing chronic pain. AP2CPS supports the trans-agency effort to accelerate opioid and pain research under HEAL. A2CPS pre-application informational webinar scheduled for September 6, 2018.
NIH releases FOA on “novel nonaddictive pain targets,” invites request for supplements for pain research, August 23, 2018
NIH 1) released a notice of intent to publish a funding opportunity announcement (FOA) regarding the discovery of “novel nonaddictive pain targets” as part of the HEAL Initiative; and 2) invited researchers to apply for supplements to ongoing research projects to expand research on pain and the identification of novel non-addictive pain targets under HEAL's trans-agency effort to accelerate opioid and pain research.
AHRQ Announces Interest in Health Services Research to Address the Opioids Crisis, August 2, 2018
The Agency for Healthcare Research and Quality (AHRQ) is interested in receiving health services research grant applications to improve pain management, opioid abuse prevention, opioid abuse treatment and recovery, and overdose prevention and treatment with special interest in evaluating state, local, and health system policy efforts, developing and evaluating interventions to prevent progression to opioid use disorders in people who are misusing or have experimented with opioids, and understanding and addressing the rapid increase in opioid-related hospitalizations among older adults.
NIDA Releases Two Notices of Intent for Funding Opportunities, July 18, 2018
The National Institute on Drug Abuse (NIDA) within the National Institutes of Health (NIH) released two notices of intent (NOI) to publish its FY2019 funding opportunity announcements (FOA) for the HEALing Communities Study.
NIH-SAMHSA Hold HEALing Communities Study Design Workshop, July 2, 2018
The National Institutes of Health (NIH) and Substance Abuse and Mental Health Services Administration (SAMHSA) hosted a workshop entitled “HEALing Communities Study Design” to solicit input on designing the HEALing Communities study.
FDA Launches Devices to Prevent and Treat Opioid Use Disorder Challenge, May 30, 2018
FDA has launched an innovation challenge to spur the development of medical devices related to Opioid Use Disorder and pain management. Submissions are due September 30, 2018. FDA held a webinar for interested participants on July 25, 2018.
Federal Opioid Research and Response Landscape, May 25, 2018
Slides from a webinar by Lewis-Burke Associates for the University’s Medical Discovery Team on Addiction.
MARRS Summit, April 6, 2018
University of Minnesota Foundation is helping organize and host the Minnesota Association of Resources for Recovery and Chemical Health (MARRCH) Shared Solutions Addiction Summit: “Addressing the Opioid Epidemic through Collaboration.”
2018 Federal Budget Bill Summary, March 23, 2018
Bill summary excerpts related to opioids from Lewis Burke Associates.
CDC Funding Announcement, March 2018
CDC has announced a funding opportunity for research grants to support prevention activities around prescription and illicit opioid overdose. Applications are due May 15, 2018; letters of intent are due by April 14, 2018.
Cross-Agency Opioid Federal Funding Opportunities, January 2018
Federal opportunities compiled by Lewis Burke Associates.
Task Force Charge Letter, January 18, 2018
Letter from President Eric Kaler.